Search Results

Takeda announced that, on October 17, 2023, it agreed with the Irish Revenue Commissioners to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc in October 2014 from AbbVie Inc., for EUR 130 million, resulting in a tax expense reduction of approximately JPY 63 billion for Takeda.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.

Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease.

The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient population with chronic neutropenia.